These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 11117673)

  • 1. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome.
    Nestler JE; Jakubowicz DJ; Iuorno MJ
    J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1295-8. PubMed ID: 11117673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.
    Baillargeon JP; Iuorno MJ; Jakubowicz DJ; Apridonidze T; He N; Nestler JE
    J Clin Endocrinol Metab; 2004 Jan; 89(1):242-9. PubMed ID: 14715857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
    Nestler JE; Jakubowicz DJ; Reamer P; Gunn RD; Allan G
    N Engl J Med; 1999 Apr; 340(17):1314-20. PubMed ID: 10219066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Myoinositol--alternative treatment of insulin resistance in adolescents].
    Kedikova S; Sirakov M; Boyadzhieva M
    Akush Ginekol (Sofiia); 2011; 50(7):16-9. PubMed ID: 22452173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
    Genazzani AD; Prati A; Santagni S; Ricchieri F; Chierchia E; Rattighieri E; Campedelli A; Simoncini T; Artini PG
    Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome.
    Cheang KI; Baillargeon JP; Essah PA; Ostlund RE; Apridonize T; Islam L; Nestler JE
    Metabolism; 2008 Oct; 57(10):1390-7. PubMed ID: 18803944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
    Papaleo E; Unfer V; Baillargeon JP; De Santis L; Fusi F; Brigante C; Marelli G; Cino I; Redaelli A; Ferrari A
    Gynecol Endocrinol; 2007 Dec; 23(12):700-3. PubMed ID: 17952759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome.
    Gupta A; Jakubowicz D; Nestler JE
    Metab Syndr Relat Disord; 2016 Oct; 14(8):391-396. PubMed ID: 27028341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.
    Baillargeon JP; Diamanti-Kandarakis E; Ostlund RE; Apridonidze T; Iuorno MJ; Nestler JE
    Diabetes Care; 2006 Feb; 29(2):300-5. PubMed ID: 16443877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
    Baillargeon JP; Iuorno MJ; Apridonidze T; Nestler JE
    Metab Syndr Relat Disord; 2010 Apr; 8(2):127-36. PubMed ID: 20156067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
    Unfer V; Porcaro G
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgens in polycystic ovary syndrome: the role of exercise and diet.
    Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
    Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions.
    Nestler JE
    J Basic Clin Physiol Pharmacol; 1998; 9(2-4):197-204. PubMed ID: 10212834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
    Croze ML; Soulage CO
    Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.
    Galletta M; Grasso S; Vaiarelli A; Roseff SJ
    Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1212-4. PubMed ID: 22165685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.
    Costantino D; Minozzi G; Minozzi E; Guaraldi C
    Eur Rev Med Pharmacol Sci; 2009; 13(2):105-10. PubMed ID: 19499845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
    Dinicola S; Chiu TT; Unfer V; Carlomagno G; Bizzarri M
    J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
    Pizzo A; Laganà AS; Barbaro L
    Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The D-chiro-inositol paradox in the ovary.
    Carlomagno G; Unfer V; Roseff S
    Fertil Steril; 2011 Jun; 95(8):2515-6. PubMed ID: 21641593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
    Minozzi M; Nordio M; Pajalich R
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.